1.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B,
Spasic M, Henry G, Ciobanu V et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
2.
Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray
S, Groh EM et al: T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. N Engl J Med 2016, 375(23):2255-2262.
3.
Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, Bukur V, Tadmor AD,
Luxemburger U, Schrors B et al: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against
cancer. Nature 2017, 547(7662):222-226.
4.
Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J,
Wong P, Ho TS et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer. Science 2015, 348(6230):124-128.
5.
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder
A, Peter L et al: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017, 547(7662):217-221.
6.
Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, Donia M, Boschen
ML, Lund-Johansen F, Olweus J et al: Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 2016, 352(6291):1337-1341.
7.
Yee C, Lizee GA: Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J 2017, 23(2):144-148.
8.
Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, Decock
J: NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives. Front Immunol 2018, 9:947.
9.
Schooten E, Di Maggio A, van Bergen En Henegouwen PMP, Kijanka MM: MAGE-A antigens as targets for cancer immunotherapy. Cancer Treat Rev 2018, 67:54-62.
10.
Gordeeva O: Cancer-testis antigens: Unique cancer stem cell biomarkers and targets for cancer
therapy. Semin Cancer Biol 2018, 53:75-89.
11.
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, Hadrup
SR, van der Minne CE, Schotte R, Spits H et al: Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature 2016, 536(7614):91-95.
12.
Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins
PF, Klebanoff CA, Rosenberg SA et al: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced
epithelial cancer. Science 2017, 356(6334):200-205.
13.
Parkhurst M, Gros A, Pasetto A, Prickett T, Crystal JS, Robbins P, Rosenberg SA: Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated
Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. Clin Cancer Res 2017, 23(10):2491-2505.
14.
Maiers M, Gragert L, Klitz W: High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007, 68(9):779-788.
15.
Zhang J, Wang L: The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technol Cancer Res Treat 2019, 18:1533033819831068.
16.
Gjerstorff MF, Andersen MH, Ditzel HJ: Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget 2015, 6(18):15772-15787.
17.
Andreatta M, Nielsen M: Gapped sequence alignment using artificial neural networks: application to the MHC
class I system. Bioinformatics 2016, 32(4):511-517.
18.
Srivastava PK: Neoepitopes of Cancers: Looking Back, Looking Ahead. Cancer Immunol Res 2015, 3(9):969-977.
19.
Klebanoff CA, Wolchok JD: Shared cancer neoantigens: Making private matters public. J Exp Med 2018, 215(1):5-7.
20.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten
M, Tabatabai G, Dutoit V, van der Burg SH et al: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019, 565(7738):240-245.
21.
Forni G: Vaccines for tumor prevention: a pipe dream? J Infect Dev Ctries 2015, 9(6):600-608.